Grants and Awards
GRANTS AND AWARDS, FY 2013
Laurie Archbald-Pannone:
- NIH/NIAID* – 1 K23 AI074681-01A1: Evaluation of C. Difficile Severity in Epidemiologic Studies & In Animal Models
Rebecca Dillingham, PI or co-PI:
- NIH Office of Disease Prevention – 1D43TW009359-01: Water and Health in Limpopo [South Africa] Innovations Fellowship Program (Co-director, R. Guerrant; project partner, University of Venda) National Science Foundation – EEC-1156999: “Research Experiences for Undergraduates” [REU] Site: Water, Society, and Health. (James Smith, PI; R. Dillingham, co-Investigator)
- NIH Career Development (K) Award – 5K23AI077339-05: Enteroaggregative Escherichia coli (EAEC) infection in HIV-infected patients in Haiti
- AIDS United; M A C AIDS: Positive Links: Smart Phones and Support for Successful Linkage to HIV Care in Rural Virginia (2 grant sources)
Joshua Eby, PI:
- NIH/NIAID – 5K08AI081900: Bordetella adenylate cyclase toxin: the role of cell interaction in toxin function
Richard Guerrant, PI:
- Bill & Melinda Gates Foundation – OPP1066140: Novel Metabonomic Biomarkers of Gut Function and Health: Modeling Enteropathy (EE) and Field Validation
- Foundation for the National Institutes of Health – Grand Challenges in Global: Gates Malnutrition & Enteric Disease program
- NIH/John E. Fogarty International Center – 1D43TW009359: Global Infectious Disease Research Training Program – The Water and Health in Limpopo Innovations Fellowship Program
- NIH/John E. Fogarty International Center – 5D43TW006578-10: Global Infectious Disease Research Training Program: UVA-Brazil (Partner institution – Federal University of Ceara, Fortaleza, Brazil)
- NIH/NIAID – 5U01AI026512-22: Long term Impact and Intervention for Diarrhea in Brazil
- University Of Maryland – SR00001830: New Therapeutics for Shiga Toxin-E. Coli Disease
- NIH/NIAID – 5U01AI075526-05: Tailoring Novel Therapeutics for Emerging Drug-Resistant C. Difficile Colitis
Erik Hewlett, PI:
- NIH/NIAID – 5R01AI018000-31: Bordetella Cyclase Toxin – Effect on Leukocytes and Respiratory Epithelial Cells
- University Of Maryland (various SR0000): MARCE2 Mid-Atlantic Regional Center of Excellence in Biodefense
- List Biological Laboratories, Inc.: Research Funding Agreement Between UVA & List Biological Laboratories
- U.S. Department of Defense/Army Research Office – W911NF-12-1-0599: Identifying a path Towards Rapid Discrimination o f Natural , Accidental and Deliberate Infection Disease Outbreaks (Co-investigator-Stephen Turner)
Scott Heysell, PI:
- NIH-NIAID – 5K23AI099019: Mentored Clinical Scientist Development Award – Clinical impact of anti-TB drug levels and M. tuberculosis susceptibility
- Burroughs Wellcome Fund/ American Society of Tropical Medicine and Hygiene: Postdoctoral Fellowship in Tropical Infectious Diseases
- Tuberculosis Foundation of Virginia, Inc.: Use of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in TB cases from Virginia
Eric Houpt, PI:
- Bill & Melinda Gates Foundation – OPP1019093: Next Generation Molecular Diagnostic Technologies for Developing Countries
- NIH/John E. Fogarty International Center – 5D43TW008270-04: Global Infectious Disease Research Training Program – UVA-Tanzania ID Training program (co-PI: Gibson Kibiki, Kilimanjaro Clinical Research Institute/Kilimanjaro Christian Medical Centre, Moshi, Tanzania)
- NIH/NIAID – 5R01AI093358-03: Tuberculosis Second Line Drug Susceptibility Chip
- NIH/NIAID – 5U01AI075396-05: Comprehensive Molecular Diagnosis for Food and Waterborne Enteropathogens
- Imperial College London – PO-2962557: London Polio
- Christian Medical College – CMC-TaqMan: India Polio
Molly Hughes, PI:
- NIH/NIAID – 1R01AI099097-01A1: Bacillus anthracis targets involved in chemokine-mediated antimicrobial activity
- Commonwealth Health Research Board – 207-03-11: Development of Novel Antimicrobial Agents for Multi-Drug Resistant Bacterial Pathogens
Barbara Mann, PI:
- NIH/NIAID – 1R56AI091746-01: Mechanisms of Francisella Virulence
- University of Maryland, Baltimore – 7762/SR00002668: Advancement of a Defined, Protective Tularemia Vaccine
William A. Petri, Jr., PI:
- NIH/NIAID – 5T32AI055432-10: Biodefense Research Training and Career Development
- NIH/NIAID – 5T32AI007046-35: Infectious Diseases Training Program
- NIH/NIAID – 5R01AI026649-24: Role of Leptin in Innate Mucosal Defense from Amebiasis
- NIH/NIAID – 5R01AI043596-14: Field Studies of Human Immunity to Amebiasis in Bangladesh
- U.S. National Center For Research Resources – 1S10RR029375-01: Flow Cytometry for BSL 3
- U.S. Department of Defense, Defense Threat Reduction Agency – HDTRA1-10-1-0082: Characterize Respiratory Pathogenes Endemic to Pakistan
- Bill & Melinda Gates Foundation – OPP1017093: Exploration of the Biologic Basis for Underperformance of OPV and Rotavirus Vaccines in Bangladesh and India
- Bill & Melinda Gates Foundation – OPP1066629: Quik Chek Rapid Immunity Assessment Test
- Bill & Melinda Gates Foundation – BMGF 51635: Study of Risk Factors for Malnutrition Using Molecular & Genomic Tools
- Techlab Research – 1 R43 AI085938-01A1: Alum-absorbed subunit vaccine to prevent intestinal amebiasis
- Techlab Research – 1 R41AI094733-01A1: Point-of-Care Test for Entamoeba histolytica Cysts
- Life Sciences Research Foundation – LSRF-K 72542: The Life Sciences Research Foundation Postdoctoral Research Fellowship (Ralston)
- University Of Maryland – SR00002327: Multi-Center Severe Diarrheal Disease Burden & Etiology Study
- The Hartwell Foundation/Hartwell Fellowship: New therapeutics for ameobiasis in children (Ralston)
- University of Washington – 749864: Accelerated Molecular Probe Pipeline UW
W. Michael Scheld, PI:
- Pfizer Pharmaceutical Labs: Pfizer Initiative in International Health 2011 Pfizer Fellowship
- Centocor Research & Development, Inc.: Golimumab Adjunctive Therapy in Experimental Murine Anthrax
- The San Francisco Aids Foundation: Academic Alliance for Aids Care
- Johnson & Johnson Pharmaceutical Research & Development: Golimumab Adjunctive Therapy in Experimental Murine Anthrax
Tania Thomas, PI:
- NIH NIAID – 5K23AI097197-02: Mentored Clinical Scientist Development Award – Improving Pediatric TB Diagnosis and Management in Tanzania
Gregory Townsend, PI:
- James Madison University – V12-313-05 & V11-287-04: JMU Part B Ryan White Medical Case Management Services; Treatment Adherence and Case Management Services
- U.S. Health Resources & Services Administration:
~ 5 H76HA04385-09: HIV Early Intervention Services (EIS) Program
~ 1H12HA24864-01-0: Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
~ 1 H97HA25002-01: HRSA HIT Capacity Building FY12-13
~ H76HA04385A0: Title III Ryan White HIV Clinical Care Grant - Virginia Department of Health – 601-611-45416-08-HIV & UVA-RWB611AU45416-1: Ryan White Financial Eligibility Screening
Cirle Warren, PI:
- Sequella, Inc. – SQ109: Trial
Wen Yuan, PI:
- NIH-NIAID – 5R33AI081616-04: Functional HIV Envelope Trimer as a Prophylactic HIV/AIDS Vaccine Candidate
- NIH-NIAID – 5R21AI087502-02: An HIV Vaccine Candidate Targeting the Coreceptor Binding Site
* NIAID = National Institute of Allergy and Infectious Diseases